- Latest available (Revised)
- Original (As made)
This is the original version (as it was originally made). This item of legislation is currently only available in its original format.
25.—(1) A product which is, or which contains, a beta-agonist or hormonal substance complies with the requirements of this regulation if—
(a)a marketing authorisation has been issued in relation to it;
(b)in the case of a product which is, or which contains, a beta-agonist, it has a withdrawal period of less than 28 days after the end of treatment; and
(c)in the case of a product which is, or which contains, a hormonal substance, it is not a product which falls within paragraph (2) below.
(2) A product falls within this paragraph if it—
(a)acts as a deposit;
(b)has a withdrawal period of more than 15 days after the end of treatment; or
(c)was authorised before 1st January 1995, has no known conditions of use and for which no reagents or equipment exists for use in the analytical techniques for detecting the presence of residues in excess of the prescribed limits.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include: